News
Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus
Pfizer Inc. (NYSE: PFE) today announced its decision to continue to progress one oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate toward further clinical development
Global Continuous Glucose Monitoring Pioneer Dexcom Reveals New Plans to Bring Sensing Technology to Millions More
Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people living with diabetes, announced today its strategy to bring Dexcom glucose sensing
Dexcom Updates Long-Range Financial Targets
DexCom, Inc. (NASDAQ:DXCM) today announced an update to its long-range financial targets at its 2023 Investor Day. Based on the company’s strong performance in the first two years of the target
FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved LITFULO™ (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older
Pfizer Declares Third-Quarter 2023 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 third-quarter 2023 dividend on the company’s common stock, payable September 5, 2023, to holders of the Common
Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Real-Time Continuous Glucose Monitoring System
Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval
Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with
Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 1, 2023. The purpose
Agilent Introduces New Comprehensive GPC/SEC Solutions at HPLC 2023 Conference
Agilent Technologies Inc. (NYSE: A) today announced they will showcase their significantly expanded InfinityLab GPC/SEC Solution at the HPLC 2023 conference on June 18 – 22, 2023 in Düsseldorf
New Study Shows That 84% of People With Diabetes Struggle With Mental Health1
As the UK marks the start of Diabetes Awareness Week, a new study reveals 84% of people surveyed agree having diabetes can negatively impact mental health.1 The study, commissioned by DexCom, Inc.
Agilent Announces BioTek 406 FX Washer Dispenser for Technology-Driven Workflow Efficiency
Agilent Technologies Inc. (NYSE: A) today announced the release of the Agilent BioTek 406 FX washer dispenser, a compact instrument that combines multifunctional reagent dispensing and
Dexcom to Host Investor Day on June 23, 2023
DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on June 23rd from 2:30 PM until approximately 5:00 PM PST (5:30 PM – 8:00 PM EST). The event will include presentations
Agilent Independent Global Lab Sustainability Survey Sheds Light on Progress Towards Greener Labs
Agilent Technologies Inc. (NYSE: A) today announced the results of an independent third-party global survey that will help the industry better understand analytical laboratories’ perceptions
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with William Pao, Chief Development Officer, Executive Vice President, at the
Agilent Announces Enhanced xCELLigence RTCA Software Pro to Support Regulatory Compliance Requirements
Agilent Technologies Inc. (NYSE: A) today announced the release of the enhanced xCELLigence RTCA Software Pro Version 2.8, an integrated software package for running and analyzing real-time cell
Agilent Announces Full Workflow for US EPA Method 1633 for Targeted PFAS Analysis
Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated, complete workflow solution for targeted per- and polyfluoroalkyl substances (PFAS) analysis using the United States (US)
Agilent Announces Inspirational LC/TQ and LC/Q-TOF Mass Spectrometry Solutions at ASMS 2023
Agilent Technologies Inc. (NYSE: A) today announced two new liquid chromatography mass spectrometry systems (LCMS), the Agilent 6495D LC/TQ and the Agilent Revident LC/Q-TOF. Facilitating the
Agilent Intelligent Mass Spectrometry Solutions to Inspire at ASMS 2023
Agilent Technologies Inc. (NYSE: A) today announced new mass spectrometry solutions on show at the 71st ASMS Conference on Mass Spectrometry and Allied Topics, being held June 4 - 8 in Houston
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and
Revvity’s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System
Revvity, Inc. (NYSE: RVTY), announced today that its EUROIMMUN business has launched the UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at William Blair's 43rd Annual Growth
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F